期刊文献+

PLGA微球制剂中艾塞那肽酰化产物的分离及活性研究 被引量:1

The separation of exenatide acylation product from PLGA micropheres and its activity study
原文传递
导出
摘要 目的:在体外释放条件下,对PLGA微球制剂中艾塞那肽的酰化产物进行分离并进行活性研究。方法:通过制备液相分离PLGA微球制剂中艾塞那肽在体外释放条件下产生的酰化产物,分别采用SD大鼠和db/db糖尿病小鼠考察艾塞那肽酰化产物的体内药动学及药效学,细胞实验进行活性研究,并与艾塞那肽进行比较。结果:艾塞那肽酰化产物为连接一个羟基乙酸的产物,药动学结果显示,酰化产物与艾塞那肽有相似的Tmax和AUC,酰化产物的Cmax略小于艾塞那肽,但药效学考察显示酰化产物可以使db/db小鼠的血糖下降,且对RIN-m5f细胞具有相似的促进胰岛细胞增殖的作用。结论:PLGA微球制剂中艾塞那肽的酰化产物与艾塞那肽原型药物有相似的降血糖作用及促进胰岛细胞增殖的作用。 Objective:To separate the related substance of exenatide formed during incubation of drug-load- ed poly-( d, 1-lactide-co-glycolide) (PLGA) microspheres under in vitro release conditions and study its activity. Methods : The acylated exenatide of exenatide-loaded microspheres was finally separated and purified by preparation liquid chromatography. The pharmacokinetic characteristics and antidiabetic activity of the acylated exenatide were investigated in SD rats and db/db mice, respectively. RIN-m5f cells were used to study the activity, and the re- sults were compared with exenatide. Results:Structural characterizations of the acylated exenatide showed that one glycolic acid (GA) was connected to the primary amine group of exenatide. Pharmacokinetie study in rats revealed that exenatide and acylated exenatide had similar had a decreased C max. However,they had similar of islet cells. Conclusion:The acylated exenatide Tmax and AUC after s. c. administration, and acylated exenatide antidiabetic activity, and both of the m could promote proliferation has a similar hypoglyeemic effect and can promote proliferation ofislet cells.
出处 《中国新药杂志》 CAS CSCD 北大核心 2016年第7期745-750,759,共7页 Chinese Journal of New Drugs
基金 国家"重大新药创制"科技重大专项--天然药物与新制剂综合大平台(2013ZX09402201) 山东省自然科学基金(ZR2013HQ009)
关键词 艾塞那肽微球 酰化产物 分离 活性研究 exenatide microspheres acylated exenatide separation activity study
  • 相关文献

参考文献8

  • 1侯书杰,才丽,李克剑,孙欧希.GLP-1类似物艾塞那肽研究进展[J].中国执业药师,2013,10(7):38-39. 被引量:14
  • 2刘延杰,季虹,林鲁霞,荣海钦.艾塞那肽的抗糖尿病机制及临床应用进展[J].中国新药与临床杂志,2011,30(6):407-411. 被引量:9
  • 3章成昌,陈建华.长效化Exendin-4的研究进展[J].现代生物医学进展,2013,13(2):371-374. 被引量:4
  • 4MURTY SB, NA DH, THANOO BC, et al. Impurity formation studies with peptide-loaded polymeric mierospheres Part II. In vitro evaluation I J ]. lnt J Pharm,2005,297 ( 1 - 2 ) :62 - 72.
  • 5MURTY SB ,THANOO BC,WEI Q,et al. Impurity formation stud- ies with peptide-loaded polymeric microspheres Part I. In vivo e- valuation [ J ]. Int J Pharm,2005,297 ( 1 - 2 ) :60 - 61.
  • 6ANDREA L,JOSEF K,ACHIM G. Peptide Aeylation by Poly(a- Hydroxy Esters) I J]. Pharm Res,2002(2) :175 - 181.
  • 7LIANG R, ZHANG R, LI X,et al. Stability of exenatide in poly (D,L-lactide-co-glycolide) solutions: a simplified investigation on the peptide degradation by the polymer E J]. Eur J Pharm Sci, 2013,50(3 -4) :502 -510.
  • 8CHAE SY,JIN CH,SHIN HJ,et al. Preparation,characterization, and application of biotinylated and biotin-PEGlated glueagon-like peptide-1 analogues for enhanced oral delivery [ J ]. Bioconjug Chem ,2008,19 ( 1 ) :334 - 341.

二级参考文献73

  • 1KWON DY, KIM YS, AHN IS, et al. Exendin-4 potentiates insulinotropic action partly via increasing beta-cell proliferation and neogenesis and decreasing apoptosis in association with the attenuation of endoplasmic reticulum stress in islets of diabetic rats[J]. J Pharmacol Sci, 2009, 111(4): 361-371.
  • 2NATALICCHIO A, de STEFANO F, ORLANDO MR, et al. Exendin-4 prevents e-Jun N-terminal protein kinase activation by tumor necrosis factor-alpha (TNFalpha)and inhibits TNFalphainduced apoptosis in insulin-secreting cells [J]. Endocrinology, 2010, 151(5) : 2019-2029.
  • 3CUNHA DA, LADRIERE L, ORTIS F, et al. Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB[J]. Diabetes, 2009, 58(12): 2851-2862.
  • 4CI-IEN J, COUTO FM, MINN AH, et al. Exenatide inhibits beta- cell apoptosis by decreasing thioredoxin-interacting protein [J]. Biochem Biophys Res Commun, 2006, 346(3): 1067-1074.
  • 5FESHE F, TRAUTMANN M, HOIST JJ, et al. Exenatide augments first-and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes [J]. J Clin Endocrinol Metab, 2005, 90(11): 5991-5997.
  • 6LI J, MURAO K, IMACHI H, et al. Exendin-4 regulates pancreatic ABCAI transcription via CaMKK/CaMKIV pathway[J]. J Cell Mol Med, 2010, 14(5): 1083-1087.
  • 7MURAO K, LI J, IMACHI H, et al. Exendin-4 regulates glucokinase expression by CaMKK/CaMKIV pathway in pancreatic beta-cell line[J]. Diabetes Obes Metab, 2009, 11 (10): 939- 946.
  • 8CHEN K, YU X, MURAO K, et al. Exendin-4 regulates GLUT2 expression via the CaMKK/CaMKIV pathway in a pancreatic beta-cell line[J]. Metabolism, 2011,60(4) :579-585.
  • 9KNAUF C, CANI PD, PERRIN C, et al. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage [J]. J Clin Invest, 2005, 115(12) : 3554-3563.
  • 10IDRIS I, PATIAG D, GRAY S, et al. Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism: contrasting effects of GLP-I[J]. Biochem Pharmacol, 2002, 63(5): 993- 996.

共引文献22

同被引文献15

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部